Isla Dolores, Lozano María D, Paz-Ares Luis, Salas Clara, de Castro Javier, Conde Esther, Felip Enriqueta, Gómez-Román Javier, Garrido Pilar, Belén Enguita Ana
Hospital Clínico Universitario Lozano Blesa, IIS Aragón, Sociedad Española de Oncología Médica (SEOM), Zaragoza, España.
Clínica Universidad de Navarra, Sociedad Española de Citología (SEC), Sociedad Española de Anatomía Patológica (SEAP), Pamplona, España.
Rev Esp Patol. 2023 Apr-Jun;56(2):97-112. doi: 10.1016/j.patol.2023.02.002. Epub 2023 Mar 28.
Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic targets, some of which have therapeutic utility. Currently, detecting EGFR, BRAF, KRAS and MET mutations, ALK, ROS1, NTRK and RET translocations, and PD-L1 expression in these patients is considered essential. The use of next-generation sequencing (NGS) facilitates precise molecular diagnosis and allows the detection of other emerging mutations, such as the HER2 mutation and predictive biomarkers for immunotherapy responses. In this consensus, a group of experts in the diagnosis and treatment of NSCLC selected by the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have evaluated currently available information and propose a series of recommendations to optimize the detection and use of biomarkers in daily clinical practice.
非小细胞肺癌（NSCLC）具有最多已确定的治疗靶点，其中一些具有治疗价值。目前，检测这些患者的表皮生长因子受体（EGFR）、BRAF、KRAS和MET突变、间变性淋巴瘤激酶（ALK）、ROS1、神经营养酪氨酸激酶（NTRK）和转染重排（RET）易位以及程序性死亡配体1（PD-L1）表达被认为至关重要。使用下一代测序（NGS）有助于精确的分子诊断，并能检测其他新出现的突变，如人表皮生长因子受体2（HER2）突变以及免疫治疗反应的预测生物标志物。在本共识中，由西班牙病理学会（SEAP）和西班牙医学肿瘤学会（SEOM）挑选的一组NSCLC诊断和治疗专家评估了当前可用信息，并提出了一系列建议，以优化日常临床实践中生物标志物的检测和使用。
